AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Resmed DRC

36.790

-1.820-4.71%

Volume:1.03M

Turnover:37.99M

Market Cap:53.62B

PE:2.58

High:37.310

Open:37.240

Low:36.790

Close:38.610

52wk High:45.042

52wk Low:31.755

Shares:1.46B

Float Shares:145.49M

Volume Ratio:0.69

T/O Rate:0.71%

Dividend:0.32

Dividend Rate:0.87%

EPS(TTM):14.238

EPS(LYR):13.444

ROE:25.68%

ROA:14.75%

PB:6.02

PE(LYR):2.74

Loading ...

Overview Company News Filings

ResMed (RMD) Is Up 5.2% After Strong Quarter, Dividend Hike And Completed Buyback Program

Simply Wall St.

ResMed Director Sells 2,000 Shares

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

ResMed Bull Anticipates Further Buybacks -- Market Talk

What ResMed (RMD)'s Earnings Beat and Completed Buyback Means For Shareholders

Simply Wall St.

ResMed Is Maintained at Equal-Weight by Wells Fargo

Top Premarket Gainers

MT Newswires Live

A Look At ResMed (RMD) Valuation As Investors Await December 2025 Earnings Report

Simply Wall St.

Earnings Beat and Cash Flow Strength Could Be A Game Changer For ResMed (RMD)

Simply Wall St.

Assessing ResMed (RMD) Valuation As Growth And Margins Improve And P/S Lingers Below Five Year Average

Simply Wall St.

ResMed Is Maintained at Hold by Stifel

Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings

MT Newswires Live

Should Goldman’s Conviction List Exit and New Stock Plans Require Action From ResMed (RMD) Investors?

Simply Wall St.

Alan Kohler: The grass is always greener on the other side

Evaluating ResMed (RMD): Is There Hidden Value After a Week of Quiet Trading?

Simply Wall St.

2 stocks Anna Milne says are best placed for healthcare’s next chapter

Will ResMed’s (RMD) Margin Expansion Define Its Role as a Defensive Portfolio Anchor?

Simply Wall St.

8 ASX names Macquarie says are ready to run in a rebound (plus a “least preferred” stock)

The ASX stocks and ETFs advisers use to build generational wealth for their kids

Morgans’ top large-cap picks for November 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":36.79,"timestamp":1770786720000,"preClose":38.61,"halted":0,"volume":1028550,"delay":0,"changeRate":-0.047138047138047146,"nameEN":"Resmed DRC","floatShares":145494856,"shares":1457529700,"eps":14.237806895871913,"marketStatus":"Closed","change":-1.82,"latestTime":"02-11 16:12:00 AEDT","open":37.24,"high":37.31,"low":36.79,"amount":37987052,"amplitude":0.013468,"askPrice":37,"askSize":1517,"bidPrice":36.75,"bidSize":1650,"shortable":3,"etf":0,"ttmEps":14.237806895871913,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":5,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":38.61,"dividendRate":0.008668,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.691284,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145494856,"roa":"14.75%","roe":"25.68%","lyrEps":13.444165,"volumeRatio":0.691284,"shares":1457529700,"dividePrice":0.318909,"high":37.31,"amplitude":0.013468,"preClose":38.61,"low":36.79,"week52Low":31.755,"pbRate":"6.02","psRate":"7.05","week52High":45.042,"institutionHeld":0,"latestPrice":36.79,"committee":0.041996,"eps":14.237806895871913,"divideRate":0.008668,"volume":1028550,"delay":0,"ttmEps":14.237806895871913,"open":37.24,"prevYearClose":35.862,"prevWeekClose":37.837,"prevMonthClose":37.458,"prevQuarterClose":35.862,"fiveDayClose":35.632,"twentyDayClose":38.416,"sixtyDayClose":38.486,"dividendPayoutRate":0.022447131800316125,"dividendGrowthYears":1,"dividendGrowthRate":0.09979072881549825,"fiveYearAvgDividendRate":0.011853610951582185},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-11","symbol":"RMD.AU","amount":0.06,"announcedDate":"2026-01-30","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-02-12","defaultRemindTime":1770764400000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-19","payableDate":"2026-02-12","currency":"USD","dateTimestamp":1770728400000,"payDate":"2026-03-19"},{"date":"2025-11-12","symbol":"RMD.AU","amount":0.06,"announcedDate":"2025-10-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-11-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-18","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1762866000000,"payDate":"2025-12-18"},{"date":"2025-08-13","symbol":"RMD.AU","amount":0.06,"announcedDate":"2025-08-01","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-08-14","defaultRemindTime":1755043200000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-18","payableDate":"2025-08-14","currency":"USD","dateTimestamp":1755007200000,"payDate":"2025-09-18"},{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610505087","title":"ResMed (RMD) Is Up 5.2% After Strong Quarter, Dividend Hike And Completed Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610505087","media":"Simply Wall St.","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610505087?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:15","pubTimestamp":1770592543,"startTime":"0","endTime":"0","summary":"In late January 2026, ResMed reported higher quarterly sales of US$1,422.81 million and net income of US$392.59 million, alongside declaring a US$0.60 per-share quarterly dividend payable on March 19, 2026, and confirming completion of a multi-year US$1.19 billion share buyback program.\nBeyond the headline results, management highlighted strong global demand for masks and devices, expanding digital health software, and supply-chain efficiencies that supported margin expansion during the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-up-52-after-strong-quarter-dividend-hike-and-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-is-up-52-after-strong-quarter-dividend-hike-and-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4567","LU2177674079.SGD","BK7501","RMD.AU","BK4585","BK4588","BK4548","RMD","BK7007","LU2008162690.USD","IE00B5TLWC47.USD","BK4082","LU0170899867.USD","BK4504"],"gpt_icon":0},{"id":"2609555597","title":"ResMed Director Sells 2,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609555597","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609555597?lang=en_us&edition=fundamental","pubTime":"2026-02-06 13:17","pubTimestamp":1770355031,"startTime":"0","endTime":"0","summary":"ResMed's (ASX:RMD) director Peter Farrell sold 2,000 of the company's common shares for an aggregate market value of $502,540 on Wednesday, according to a US Securities and Exchange Commission disclosure filed with the Australian bourse on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK4588","RMD","BK7007","BK4567","BK4504","BK4548","IE00B5TLWC47.USD","LU2008162690.USD","BK4082","LU2177674079.SGD","LU0170899867.USD","BK4585","RMD.AU"],"gpt_icon":0},{"id":"2609532874","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2609532874","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609532874?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:25","pubTimestamp":1770344732,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday.Liberty Financial Group : +5%, AU$4.13ResMed : +2%, AU$38.24Brambles : +2%, AU$23.13Smartgroup : +1%, AU$8.60PEXA Group : +1%, AU$13.75Gryphon Capital Income Trust : +1%, AU$2.08Rio Tinto Group : +1%, AU$158Woolworths Group : +1%, AU$31.78Aussie Broadband : +0.5%, AU$4.37National Storage REIT : +0.2%, AU$2.76","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK7010","BK7004","WOW.AU","BK7015","BK7507","BK7123","SIQ.AU","BK7151","BK7511","BK7057","ABB.AU","BK7160","GCI.AU","BK7064","BK7007","NSR.AU","BXB.AU","LFG.AU","RIO.AU","PXA.AU","BK7501","RMD.AU","BK7040"],"gpt_icon":0},{"id":"2608391880","title":"ResMed Bull Anticipates Further Buybacks -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2608391880","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608391880?lang=en_us&edition=fundamental","pubTime":"2026-02-02 08:30","pubTimestamp":1769992200,"startTime":"0","endTime":"0","summary":"0030 GMT - ResMed's bull at Morgan Stanley reckons that the breath-tech provider's strong balance sheet can support continued share buybacks over its next six quarters. Analyst David L. Bailey tells clients in a note that he assumes a buyback of US$175 million in both of the third and fourth quarters, taking the fiscal 2026 total to US$675 million. He sees capacity for more to follow thanks to ResMed's strong cash flow generation, with US$175 million per quarter anticipated through fiscal 2027. He forecasts a net cash position of US$1.6 billion at the end of fiscal 2027, which suggests acquisitions are also an option. MS keeps a US$310.00 target price and overweight rating on ResMed's U.S.-listed stock, which last closed at US$258.31. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","LU1548497426.USD","LU1732800096.USD","LU0106261372.USD","LU0106831901.USD","LU2357305700.SGD","LU0314104364.USD","LU2028103732.USD","BK4567","BK4516","LU0170899867.USD","LU1074936037.SGD","LU2089283258.USD","LU0882574139.USD","LU0267386448.USD","LU1989772923.USD","LU1668664300.SGD","BK4082","LU0795875169.SGD","BK4581","LU2133065610.SGD","LU1791710400.SGD","LU2347655156.SGD","LU1720051017.SGD","LU2008162690.USD","RMD.AU","LU0557290698.USD","LU0528227936.USD","RMD","LU0912757837.SGD","BK4548","LU0098860793.USD","IE00BKVL7J92.USD","LU1989772840.SGD","LU2111349929.HKD","LU0320765646.SGD","LU2271345857.HKD","LU1162221912.USD","IE00B5TLWC47.USD","LU0971096721.USD","LU1791710582.SGD","LU0795875086.SGD","LU1244550221.USD","LU0158827948.USD","LU0234570918.USD","BK4585","LU1244550577.SGD","LU2023251221.USD","BK7007","LU1720051108.HKD"],"gpt_icon":0},{"id":"2608884167","title":"What ResMed (RMD)'s Earnings Beat and Completed Buyback Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884167","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608884167?lang=en_us&edition=fundamental","pubTime":"2026-02-02 01:19","pubTimestamp":1769966399,"startTime":"0","endTime":"0","summary":"In late January 2026, ResMed reported past fiscal second-quarter results showing sales of US$1,422.81 million and net income of US$392.59 million, alongside a US$0.60 per-share quarterly dividend and completion of a long-running share repurchase program totaling US$1.19 billion. \nThe combination of double-digit revenue and earnings per share growth, strong demand for masks and digital health software, and ongoing capital returns underscored management’s focus on both business expansion and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/what-resmed-rmds-earnings-beat-and-completed-buyback-means-f","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/what-resmed-rmds-earnings-beat-and-completed-buyback-means-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD.AU"],"gpt_icon":0},{"id":"2607042474","title":"ResMed Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607042474?lang=en_us&edition=fundamental","pubTime":"2026-01-30 23:33","pubTimestamp":1769787180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 10:33 ET (15:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","BK4567","LU0211328371.USD","LU0648001328.SGD","LU0971096721.USD","LU1894683348.USD","LU0128525929.USD","LU0289960550.SGD","LU0640476718.USD","BK4548","BK4559","LU0072461881.USD","LU2361045086.USD","IE00B7SZLL34.SGD","LU0170899867.USD","LU2361044949.HKD","LU1267930490.SGD","LU0980610538.SGD","LU0162691827.USD","LU2361044865.SGD","IE0002270589.USD","LU0048573561.USD","LU0154236417.USD","LU2008162690.USD","LU2177674079.SGD","LU1791807156.HKD","BK4504","LU1267930227.SGD","LU0708994859.HKD","BK7007","BK4585","LU1668664300.SGD","LU0256863811.USD","IE00B19Z3581.USD","RMD","LU0477156953.USD","IE000M9KFDE8.USD","LU0417517546.SGD","LU1814569148.SGD","LU1201861249.SGD","LU0310800965.SGD","LU0683600562.USD","BK4588","BK7501","RMD.AU","LU1267930573.SGD","LU0128525689.USD","LU0787776722.HKD","LU0130517989.USD","LU0130102774.USD"],"gpt_icon":0},{"id":"2607170770","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2607170770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607170770?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:08","pubTimestamp":1769774938,"startTime":"0","endTime":"0","summary":"VivoSim Labs  shares were up 70% in recent Friday premarket activity, a day after the pharmaceutical and biotechnology services company signed agreements designating JCBio as its distributor in South Korea and Tekon Biotech in China for its NAMKind toxicology services.Twin Hospitality  stock was up 72%, erasing Thursday's loss.Deckers Outdoor  stock was up 13%, a day after the company posted higher fiscal Q3 earnings and net sales, and raised its fiscal 2026 outlook.ResMed  shares were 4% higher after the company posted overnight higher fiscal Q2 adjusted earnings and revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RMD","BK4082","TWNP","BK4504","DECK","BK4209","BK4139","BK7501","LU2177674079.SGD","BK4567","BK7007","LU0170899867.USD","TWNPQ","BK4588","IE00B5TLWC47.USD","BK4548","LU0266013472.USD","VIVS","BK4585","BK4146","RMD.AU","LU2008162690.USD"],"gpt_icon":0},{"id":"2606268604","title":"A Look At ResMed (RMD) Valuation As Investors Await December 2025 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2606268604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606268604?lang=en_us&edition=fundamental","pubTime":"2026-01-25 22:30","pubTimestamp":1769351459,"startTime":"0","endTime":"0","summary":"Upcoming earnings as the key near term catalyst\nResMed (RMD) heads into its upcoming December 2025 quarter earnings report on January 29 with market attention squarely on whether results match expectations, as recent analyst commentary has turned somewhat cautious.\nSee our latest analysis for ResMed.\nResMed’s recent share price moves have been mixed, with a 3.1% 1 month share price return but a 2.6% 3 month share price decline. A 1 year total shareholder return of 1.6% and 5 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/a-look-at-resmed-rmd-valuation-as-investors-await-december-2","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/a-look-at-resmed-rmd-valuation-as-investors-await-december-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","RMD.AU"],"gpt_icon":0},{"id":"2603696624","title":"Earnings Beat and Cash Flow Strength Could Be A Game Changer For ResMed (RMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603696624","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603696624?lang=en_us&edition=fundamental","pubTime":"2026-01-16 16:24","pubTimestamp":1768551858,"startTime":"0","endTime":"0","summary":"In its most recent quarter, ResMed reported past revenues of US$1.34 billion, up 9.1% year on year, with earnings per share exceeding analyst expectations while revenue aligned with forecasts.\nThe results highlighted ongoing revenue growth, rising profitability, and stronger free cash flow, reinforcing the company’s progress in cloud-connected respiratory care and home-based sleep solutions.\nNext, we’ll examine how this earnings beat on profitability, alongside steady revenue expansion,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/earnings-beat-and-cash-flow-strength-could-be-a-game-changer","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/earnings-beat-and-cash-flow-strength-could-be-a-game-changer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD.AU"],"gpt_icon":0},{"id":"2603767434","title":"Assessing ResMed (RMD) Valuation As Growth And Margins Improve And P/S Lingers Below Five Year Average","url":"https://stock-news.laohu8.com/highlight/detail?id=2603767434","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603767434?lang=en_us&edition=fundamental","pubTime":"2026-01-15 11:29","pubTimestamp":1768447796,"startTime":"0","endTime":"0","summary":"ResMed (RMD) is back on investor radars after recent data highlighted its revenue and earnings growth, improving free cash flow margins, and a share price sitting below its five year average P/S multiple.\nSee our latest analysis for ResMed.\nThe recent 1-day share price return of 1.90% and 7-day share price return of 4.55% suggest some short term momentum is building, even though the 90-day share price return of 3.89% points to a softer patch. At the same time, a 1-year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/assessing-resmed-rmd-valuation-as-growth-and-margins-improve","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/assessing-resmed-rmd-valuation-as-growth-and-margins-improve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD","BK4548","LU2177674079.SGD","DCF","BK4082","BK7007","BK4504","IE00B5TLWC47.USD","LU2008162690.USD","LU0170899867.USD","RMD.AU","BK7501","BK4588","BK4567","BK4585"],"gpt_icon":0},{"id":"2592064519","title":"ResMed Is Maintained at Hold by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2592064519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592064519?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:13","pubTimestamp":1766063580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 08:13 ET (13:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4567","BK7007","RMD.AU","BK4548","LU2008162690.USD","RMD","BK4585","BK4082","BK4504","BK7501","LU0170899867.USD","LU2177674079.SGD","IE00B5TLWC47.USD","BK4127","BK4588"],"gpt_icon":0},{"id":"2590398118","title":"Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2590398118","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590398118?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:41","pubTimestamp":1765244498,"startTime":"0","endTime":"0","summary":"Shares of Resmed  fell 2% on recent Tuesday trade after it received US Food and Drug Administration clearance for a medical device that provides personalized comfort settings to help people with obstructive sleep apnea stay on Continuous Positive Airway Pressure  therapy, according to a Monday statement.The device will launch in early 2026, the statement said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","RMD.AU","BK7007"],"gpt_icon":0},{"id":"2588043160","title":"Should Goldman’s Conviction List Exit and New Stock Plans Require Action From ResMed (RMD) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043160","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043160?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:16","pubTimestamp":1764760581,"startTime":"0","endTime":"0","summary":"ResMed recently saw Richard Sulpizio step down from its board and filed two employee stock ownership-related shelf registrations totaling about US$1.32 billion in common stock, while Goldman Sachs removed the company from its APAC Conviction List.\nTogether, these moves highlight a mix of ordinary corporate housekeeping and a meaningful reassessment by a major broker that could reshape how investors view ResMed’s prospects.\nNext, we’ll explore how Goldman Sachs’ decision to drop ResMed from...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/should-goldmans-conviction-list-exit-and-new-stock-plans-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/should-goldmans-conviction-list-exit-and-new-stock-plans-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0170899867.USD","LU0345770308.USD","LU2471134796.USD","BK4533","BK4516","BK4585","BK7501","BK4127","BK4552","LU0251131958.USD","LU2471134523.USD","ISBC","LU2471134879.HKD","IE00BSNM7G36.USD","LU0048573561.USD","BK4082","LU0096364046.USD","BK4548","LU0106831901.USD","LU2750360641.GBP","IE00BFXG1179.USD","IE00B5TLWC47.USD","RMD.AU","LU2237443622.USD","LU2237443465.HKD","IE00B19Z3B42.SGD","BK4504","LU2750360997.AUD","LU2471134952.CNY","LU1868836914.USD","LU2177674079.SGD","LU2237443382.USD","BK7007","LU1804176565.USD","LU0251142724.SGD","LU1668664300.SGD","IE0004086264.USD","BK4588","IE0004091025.USD","BK4211","LU1868837300.USD","LU1894683348.USD","LU2237438978.USD","LU2265009873.SGD","LU1791807156.HKD","LU2237443549.SGD","LU0345770993.USD","LU2237443978.SGD","RMD","LU2008162690.USD"],"gpt_icon":0},{"id":"2586299378","title":"Alan Kohler: The grass is always greener on the other side","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299378","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299378?lang=en_us&edition=fundamental","pubTime":"2025-11-27 08:30","pubTimestamp":1764203407,"startTime":"0","endTime":"0","summary":"Investors are hardwired to compare themselves with whatever is running hottest at the time. When US tech stocks roar, the temptation is to look at the ASX and wonder why we bother. Yet Alan Kohler, one of the most recognisable voices in Australian finance, is entirely at ease with the slower and steadier returns on home soil. And after decades watching market cycles come and go, he has a simple message for anyone feeling twitchy about missing out.“We probably shouldn’t get too greedy,” he says.The local market has delivered a modest gain this year, but once you factor in dividends, total returns are north of 7 percent with a month still to run.It feels unremarkable only when stacked against the US, where the S&P 500 has surged on the back of an AI-fuelled boom. But Kohler’s view is that the extra sizzle in the US comes with baggage that many investors tend to forget until it is too late.Nvidia continues to deliver big numbers, but the market is slowly realising that its customer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/alan-kohler-the-grass-is-always-greener-on-the-other-side","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/alan-kohler-the-grass-is-always-greener-on-the-other-side","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0466842654.USD","LMG.AU","BK4579","NVD3.UK","LU2750360641.GBP","NVDS","NVD2.UK","XJO.AU","BK4567","NVD","LU2592432038.USD","LU1935043023.USD","LU1551013342.USD","LU1066051498.USD","LU1815333072.USD","LU1116320737.USD","LU1868836591.USD","ARU.AU","LU0345770308.USD","NVDS.UK","XKO.AU","BK4554","LU2108987350.USD","BK7508","RMD.AU","LU2244417387.USD","NVIW.SI","LU2473716301.USD","NVDD","SNVD.UK","LU2125909247.SGD","LU1934455277.USD","NVDA","LU1267930730.SGD","LU2413666699.HKD","NVDY","XAO.AU","COH.AU","LU0203202063.USD","NVDU","IE00BDCRKT87.USD","LU0689626769.HKD","2NVD.UK","3NVD.UK","SRL.AU","CSL.AU","LU0683600562.USD","LU0342679015.USD"],"gpt_icon":1},{"id":"2586288981","title":"Evaluating ResMed (RMD): Is There Hidden Value After a Week of Quiet Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586288981","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586288981?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:20","pubTimestamp":1764109217,"startTime":"0","endTime":"0","summary":"ResMed (RMD) shares have drawn attention following a muted day in the market, with a slight dip of less than 1%. Investors may be weighing the company’s steady long-term track record in comparison to recent short-term fluctuations.\nSee our latest analysis for ResMed.\nResMed's 1-year total shareholder return sits at 1.3%, reflecting a period where momentum has been slow to build. There have still been some strong long-term gains, such as a 14% total return over three years. Recent price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/evaluating-resmed-rmd-is-there-hidden-value-after-a-week-of","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/evaluating-resmed-rmd-is-there-hidden-value-after-a-week-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4504","IE00B5TLWC47.USD","LU2008162690.USD","LU2177674079.SGD","BK4585","RMD","BK4567","BK4588","RMD.AU","BK7501","BK4548","LU0170899867.USD","BK7007","BK4082"],"gpt_icon":0},{"id":"2585154202","title":"2 stocks Anna Milne says are best placed for healthcare’s next chapter","url":"https://stock-news.laohu8.com/highlight/detail?id=2585154202","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585154202?lang=en_us&edition=fundamental","pubTime":"2025-11-21 04:00","pubTimestamp":1763668815,"startTime":"0","endTime":"0","summary":"While healthcare headlines often focus on breakthroughs or budget battles, the real drivers of the next decade are slower, larger, and far more structural.Among those forces, none looms larger than demographics, a shift that is quietly reshaping demand, delivery models, system capacity, and long-term investment returns.Over the past week, I’ve been speaking with specialists across key sectors to understand how long-run forces are transforming the investing landscape.I’ve spoken with Dr David Walsh and Dr Wang Chun Wei from RQI on the AI and technology front, and with ClearBridge’s Michael Slack on the materials side.In the healthcare domain, my conversation with Anna Milne from Wilson Asset Management offered a timely perspective on how demographic pressures are redefining the sector.“Australia already spends more than the OECD average as a percentage of GDP on healthcare, yet this figure will continue to rise. This is not a choice; demand is increasing, and only so many funding cuts c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/2-stocks-anna-milne-says-are-best-placed-for-healthcare-s-next-chapter","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/2-stocks-anna-milne-says-are-best-placed-for-healthcare-s-next-chapter","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MPL.AU","BK7501","BK7089","RMD.AU","BK7007"],"gpt_icon":0},{"id":"2584495614","title":"Will ResMed’s (RMD) Margin Expansion Define Its Role as a Defensive Portfolio Anchor?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495614","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584495614?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:19","pubTimestamp":1763464764,"startTime":"0","endTime":"0","summary":"Recent analyst commentary highlights ResMed's strong fundamentals, including expanding margins, robust cash flow, and resilience against economic downturns, as key reasons for optimism about the company's future prospects.\nThis focus on financial stability and operational efficiency has drawn increased investor attention, especially for those seeking portfolio protection during uncertain economic conditions.\nWe'll explore how ResMed's proven financial resilience and operational strengths may...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/will-resmeds-rmd-margin-expansion-define-its-role-as-a-defen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/will-resmeds-rmd-margin-expansion-define-its-role-as-a-defen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD.AU","BK7501","BK4588","LU2177674079.SGD","BK4567","IE00B5TLWC47.USD","LU0170899867.USD","BK4504","RMD","BK4548","BK4585","LU2008162690.USD","BK4082","BK7007"],"gpt_icon":0},{"id":"2584676626","title":"8 ASX names Macquarie says are ready to run in a rebound (plus a “least preferred” stock)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584676626","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584676626?lang=en_us&edition=fundamental","pubTime":"2025-11-18 04:00","pubTimestamp":1763409620,"startTime":"0","endTime":"0","summary":"The equity gods may have cast rainy days over the Australian sharemarket, but Macquarie encourages investors not to despair - rather, to prepare for opportunity.Market Index data shows the ASX 200 is down over 5%from its 21 October record high and was within a whisker of a five-day losing streak. It alsobriefly touched its 200-day moving averagefor the first time since late April.But, for patient investors, bad news is good news. Right?In a report published yesterday, Macquarie's analysts point to the positives.equities into 2026. Australia's consumer is the most optimistic in years,while business conditions are improving. Ex-US global momentum is still. indigestion for equities as RBA cuts have been priced out, and a similar. \"We think we are in a correction, as leading indicators are improving.That said, another Fed cut would help stocks regain momentum,\" Macquarie says.“If we're right that this is a correction, the ASX 200 should find more support near the 200-day . We think a rebou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/8-asx-names-macquarie-says-are-ready-to-run-in-a-rebound-plus-a-least-preferred-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/8-asx-names-macquarie-says-are-ready-to-run-in-a-rebound-plus-a-least-preferred-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7503","AFG.AU","BK7043","MQG.AU","BK7015","BK7511","BK7051","XKO.AU","AGM.AU","BK7007","AGM","BK7123","BK7143","WTC.AU","XJO.AU","MP1.AU","ABB.AU","APE.AU","AOV.AU","BK7078","BK7501","BK4195","BK4229","XAO.AU","BK7046","JIN.AU","RMD.AU","BK7160","BK7016"],"gpt_icon":0},{"id":"2583304001","title":"The ASX stocks and ETFs advisers use to build generational wealth for their kids","url":"https://stock-news.laohu8.com/highlight/detail?id=2583304001","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583304001?lang=en_us&edition=fundamental","pubTime":"2025-11-13 04:00","pubTimestamp":1762977609,"startTime":"0","endTime":"0","summary":"Some days it feels like we’re constantly caught between two extremes - worrying about when the AI overlords will take over and make us all irrelevant, then next minute, stressing about what’s for dinner.But somewhere in the middle sits the question that really matters: how do we give our kids the best possible start in life - financially, at least?We’ve already covered the basics of investing for children and grandchildren. This time, I wanted to go a step further. What does it actually look like in practice?How do the professionals do it for their own families?So, I asked the following three seasoned experts to open their books and share exactly how they’re setting their kids up for the long run.David Lane, Ord Minnett:ETFs, discipline and a long-term mindset. “My children are now young adults . Our eldest two have completed their university education and are working full-time, while our youngest is a full-time university student with three different casual jobs,” he says.Like any cau","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-stocks-and-etfs-advisers-use-to-build-generational-wealth-for-their-kids","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-stocks-and-etfs-advisers-use-to-build-generational-wealth-for-their-kids","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4588","VGAD.AU","FDN","QUAL","XJO.AU","RMD.AU","BK4585","BK7501","AUMF.AU","BK4550","BK7079","BRN.AU","IOO.AU","IEM.AU","XAO.AU","QUAL.AU","BK7016","GOLD.AU","XKO.AU","STW.AU","IOZ.AU","BK7054","BK7007","VAS.AU","QUB.AU","HYGG.AU","IAF.AU"],"gpt_icon":0},{"id":"2580768932","title":"Morgans’ top large-cap picks for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580768932","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580768932?lang=en_us&edition=fundamental","pubTime":"2025-11-04 10:35","pubTimestamp":1762223757,"startTime":"0","endTime":"0","summary":"After two consecutive years of aggregate earnings decline, the ASX 200 is. forecast to return to growth, with earnings expected to rise 5.7% in FY26 and. we see this as limiting multiple expansion rather than signalling downside price. risk. But concentration risk and ongoing macroeconomic tremors will continue to. see significant stock divergence, and investors will need to remain nimble and on. Although the financial year-end of most Australian businesses is the end of June,many important listed companies report to the end of March and September.This month, we update our large-cap Best Ideas, adding Aristocrat and removing Treasury Wine Estates, WiseTech and Light & Wonder.CSL is looking to simplify operations and reduce complexity to enhance agility and performance. CSL will hold a Capital Markets Day in the US from November 4–6, 2025, to provide further details on its strategy, this will be important to help investors regain confidence.oil prices, if any volatility were to unfold i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/morgans-top-large-cap-picks-for-november-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/morgans-top-large-cap-picks-for-november-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7078","BK4533","BK4585","BK7501","BK7016","BK7508","BK7506","BK4597","BK7063","BK7097","BK4114","BK7511","LU0310800965.SGD","LU1244550494.USD","BK7155","RMD.AU","LU1267930227.SGD","AMC.AU","TGT","LU2237443622.USD","BK7099","NST.AU","BK7142","GMG.AU","LU0052756011.USD","LU1244550221.USD","BK7503","BK4504","BK7067","BK4155","LU1267930490.SGD","LU0211328371.USD","ALL.AU","WDS.AU","LNW.AU","LU0128525689.USD","LU2237443382.USD","WTC.AU","LU0310799852.SGD","BK7007","LU1244550577.SGD","LU0823411888.USD","BK4588","BK4532","CSL.AU","BK7505","LU2237443978.SGD","TWE.AU","LU0211327993.USD","BK4596"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}